In short
- Revenue increased 1.9% year on year to ¥50.1 billion, while EBITDA decreased 16.7% to ¥7.4 billion.
- The company will transfer 47 医心館 facilities, primarily in western Japan, for ¥17.4 billion and expects a gain on sale of approximately ¥7.9 billion in the fiscal year ending September 2027.
- For the fiscal year ending September 2027, revenue of ¥35.6 billion and operating profit of ¥1.1 billion are forecast, while net income is expected to reach ¥5.3 billion due to the gain on sale.
What they reported
this period against the same period a year earlier, and where they now expect the year to endSales
| Period | ¥bn |
|---|---|
| FY24/9 Q1 | 9.5 |
| FY24/9 Q2 | 10.1 |
| FY24/9 Q3 | 11.1 |
| FY24/9 Q4 | 11.8 |
| FY25/9 Q1 | 11.8 |
| FY25/9 Q2 | 12.0 |
| FY25/9 Q3 | 12.5 |
| FY25/9 Q4 | 12.8 |
| FY26/9 Q1 | 12.9 |
| FY26/9 Q2 | 12.7 |
| FY26/9 Q3 | 12.7 |
Revenue increased due to the opening and ramp-up of facilities.
施設稼働率が低下しているものの、施設の開設と立ち上がりにより増収Revenue is expected to decline in the fiscal year ending September 2027 due to the transfer of the 医心館 business and other factors.
医心館事業が減収減益となるため売上と営業利益は前年比で減少Operating profit
| Period | ¥bn |
|---|---|
| FY24/9 Q1 | 2.6 |
| FY24/9 Q2 | 2.7 |
| FY24/9 Q3 | 2.8 |
| FY24/9 Q4 | 2.5 |
| FY25/9 Q1 | 2.0 |
| FY25/9 Q2 | 1.7 |
| FY25/9 Q3 | 1.0 |
| FY25/9 Q4 | 1.5 |
| FY26/9 Q1 | 1.6 |
| FY26/9 Q2 | 1.2 |
| FY26/9 Q3 | 0.8 |
Profit declined due to higher personnel expenses and the impact of revisions to medical service fees.
シフトチェンジによる人件費上昇と診療報酬改定による影響で、EBITDAは減少Operating profit of ¥1.1 billion is forecast for the fiscal year ending September 2027.
Net profit
| Period | ¥bn |
|---|---|
| FY24/9 Q1 | 1.8 |
| FY24/9 Q2 | 2.0 |
| FY24/9 Q3 | 1.9 |
| FY24/9 Q4 | 1.7 |
| FY25/9 Q1 | 1.3 |
| FY25/9 Q2 | 1.3 |
| FY25/9 Q3 | 0.3 |
| FY25/9 Q4 | 0.7 |
| FY26/9 Q1 | 1.1 |
| FY26/9 Q2 | 0.8 |
| FY26/9 Q3 | 0.6 |
A substantial increase in profit is expected due to the gain on the sale of the western Japan area.
医心館西日本エリアの譲渡益の計上により当期純利益は大幅増益Dividend
Shareholder dividends: The basic policy is to maintain stable shareholder dividends, taking comprehensive account of market conditions, regulatory trends and financial soundness, and to pay an annual year-end dividend.
Their own numbers
figures this company chose to report, a year ago against nowUtilization of existing facilities was 73.8%.
Utilization of new facilities opened in the fiscal year ended September 2026 was 41.0%.
The number of facilities at the end of the period increased from 130 in the previous year to 138.
The number of beds at the end of the period increased from 6,706 in the previous year to 7,178.
The in-facility end-of-life care rate was 98.9%.
Average customer satisfaction was 8.80 points.
The low–high ranges are Komori's estimate, not figures the company gave.
Everything else in the deck
By business
What moved
New initiatives
- The company will transfer 47 医心館 facilities, primarily in western Japan, to NSSK and concentrate its management resources on the Tokyo metropolitan area and eastern Japan.
- The comprehensive medical support business offers 3 services: management consulting, financial support and trading company functions.
- The Company will establish AIZIA, a subsidiary responsible for developing and selling DX/AI systems, among other activities, and expand into the healthcare, nursing care and welfare sectors.
- The Ishinkan medical care facility business will be entrusted to the next generation, while senior management focuses on company-wide strategy and expanding growth areas.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckMargins and overheads
Financial targets
| Period | % |
|---|---|
| FY21/9 | 24.4 |
| FY22/9 | 23.3 |
| FY23/9 | 26.9 |
| FY24/9 | 24.9 |
| FY25/9 | 10.6 |
| Period | % |
|---|---|
| FY21/9 | 51.2 |
| FY22/9 | 49.0 |
| FY23/9 | 47.7 |
| FY24/9 | 46.3 |
| FY25/9 | 43.0 |
| Period | % |
|---|---|
| FY21/9 | 8.0 |
| FY22/9 | 6.8 |
| FY23/9 | 4.7 |
| FY24/9 | 5.3 |
| FY25/9 | 10.7 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.
How they rate themselves against plan
On a consolidated basis, revenue and net income fell below the initial forecasts, while EBITDA and operating profit met them, and the comprehensive medical support business significantly exceeded its initial forecast.
営業利益、経常利益で期初予想を達成The line is the plan; a bar grows right by how far the result beat it and left by how far it missed, as a share of the plan.
Assumptions behind the forecast
Store or site count
Market size and share
The company's slice (blue) is drawn magnified so a small share stays visible; compare it with its own dashed outline from a year ago.